Page 1 of 2 12 LastLast
Results 1 to 10 of 13

Thread: DA is a genius...

  1. #1
    Senior Member
    Join Date
    Apr 2002
    katonah , ny, usa

    DA is a genius...

    Today in the NY Times- stem cells can cure forms of blindness due to injury and/or disease. Transplants continue to move forward, with majority of those helped, having their lives changed forever! Hip Hip Hooray!!!!!
    Spinal cord stem treatments must go through at least 5-7 years of more animal studies before trials even start!!

    are we a threat to societty? If they can work with humans while doing trials for stem cell therapies for eyes, SCI should be ahead! I think SCI might be easier to fix!

    sherman brayton

  2. #2
    Senior Member Schmeky's Avatar
    Join Date
    Sep 2002
    West Monroe, LA, USA

  3. #3

  4. #4
    Senior Member foster's Avatar
    Join Date
    Dec 2001
    bensalem Pa usa
    To many happy people in wheelchairs. Not enough wheelchair user piss off.

  5. #5
    Senior Member
    Join Date
    Apr 2002
    katonah , ny, usa
    I will not accept any answer from, even Dr. Young! Doctors have not even started clinical trials for stem cell eye repair, but an average of 60 people are being worked on today.
    Why has this form of stem cell research jump righ into human testing? Tetra and paraplegia in my view is a tougher road than blindness.
    In the NY Times article doctors cautioned, " these transplants will not restore your site to 20/20, but you will make small improvements over time."
    Someone at the top is stalling SCI therapies, I cannot accept any excuse while this is happening with blind individuals.

    sherman brayton

  6. #6
    yeah foster, we could threaten not to walk anymore or not to work- that'd teach them.....WAIT A MINUTE!

    "I saw the best minds of my generation destroyed by madness, starving hysterical naked..."
    - Allen Ginsburg

  7. #7

    Have you considered the possibility that blind people have been much better organized and successful in getting funding for research and clinical trials than the spinal cord injury community? Did you know that there is an entire institute at NIH devoted to blindness research? Called the National Eye Institute, their 2003 budget is $692 million.

    We would have more clinical trials in spinal cord injury if there were funding.


  8. #8
    Here was a study funded by NEI showing that stem cells may be helpful in mice with diabetic retinopathy,

    Stem Cells from Bone Marrow May Help Mend Eyes
    Mon Jul 29, 2002
    By Merritt McKinney

    NEW YORK (Reuters Health) - New research in mice suggests stem cells collected from bone marrow could be used to treat several sight-robbing eye diseases that involve abnormal blood vessel growth.

    When injected into the eyes of newborn mice, the stem cells grew into blood vessels, and may have prevented the loss of vision that normally occurs in this type of mouse.

    The results of the animal experiments are encouraging, but there is a long way to go before human studies can start, since it is uncertain whether the same cells exist in people, according to the study's lead author, Dr. Martin Friedlander, of The Scripps Research Institute in La Jolla, California.

    "If it works, it would be great," he told Reuters Health in an interview.

    Several common eye diseases involve abnormalities in the blood vessels in the retina, the light-sensitive layer located on the inner surface of the back of the eye.

    Diabetic retinopathy, a cause of blindness in diabetics, and age-related macular degeneration, the number one cause of blindness in the elderly, are both characterized by the growth of too many blood vessels. An inherited condition, retinitis pigmentosa, can cause blindness because blood vessels in the retina degenerate.

    Friedlander and his colleagues studied a type of stem cell commonly found in bone marrow called a hematopoietic stem cell. Such stem cells have the capability to form the cells of the blood and immune system. However, there is also a subset of cells, called endothelial precursor cells, or EPCs, that form blood vessels.

    According to the study in an advance online publication of the September issue of Nature Medicine, Friedlander and his colleagues report that hematopoietic stem cells that contain lots of EPCs can be used to promote and inhibit the growth of blood vessels in the retina.

    The researchers injected EPC-enriched hematopoietic cells into the eyes of baby mice that had a disease similar to retinitis pigmentosa. The cells interacted with a second type of cell known as an astrocyte and "completely rescued" the at-risk blood vessels, Friedlander said. The mice went on to develop completely normal blood vessels in the retina, he said.

    The California researcher added that the treatment also seemed to rescue some photoreceptors, structures that are destroyed in retinitis pigmentosa. Though the results raise the possibility of using bone marrow cells to treat retinitis pigmentosa in people, Friedlander said that it is "still to be seen" whether vision is restored in the mice.

    The bone marrow cells also seem promising for the treatment of eye diseases marked by too many blood vessels, according to Friedlander. The researchers genetically engineered the EPCs to produce a powerful substance that prevents blood vessel growth, and were able to interfere with the formation of blood vessels in the retina.

    The cells may also help in treating diabetic retinopathy, a condition in which new blood vessels grow because the eye is not getting enough oxygen. Unfortunately, these new blood vessels leak and otherwise wreak havoc on the eye.

    The traditional approach, Friedlander said, has been to develop ways to stop new blood vessels from forming. But this only treats the symptoms and does not solve the problem of inadequate oxygen for the eyes.

    Friedlander speculated that it might be possible to stop diabetic eye disease by injecting bone marrow cells into the eyes of diabetics in the early stages of the disease. The stem cells would be expected to encourage the growth of normal blood vessels to supply oxygen but would prevent too many vessels from forming. The researcher cautioned, however, that this approach has not even been tested in mice, much less in people.

    The study was funded by the National Eye Institute and several other government and not-for-profit sources.

  9. #9

    Is this the article that you are referring to? Is so, please read article again. They are using the so-called "stem cells" from another eye to repair corneal damage. These are not the "stem cells" that you think they are.


    Here is the New York Times article:

    Stem Cell Transplants Offer New Hope in Some Cases of Blindness

    little-known operation restores hope for people who lose sight from chemical or heat burns of the eye or certain rare diseases. The procedure, 50 to 100 percent effective in healing corneal damage, is used worldwide, including Iran, where it helps restore sight for victims of Iraqi mustard gas attacks.

    A variation on corneal transplants, the surgery grafts stem cells from a donor or a patient's good eye to the injured eye. The cells are from the limbus, a rim around the cornea. The cells resheath the cornea's surface, the 50-micron-thick epithelium, to maintain it as a transparent window. When burns or disease wipe out the limbal stem cells, the epithelium clouds over with scar tissue, causing blindness.

    Grafting even a small piece of limbus can lead the stem cells to regrow clear epithelium - and keep it clear - thus restoring sight. The cells even recover transplanted corneas. Stem cell transplants and corneal transplants are frequently performed one after the other if corneal damage extends below the epithelium.

    The discovery of the cells 17 years ago and clinical proof that they keep working in any eye with an intact tear system has opened a new era in eye surgery.

    "It's an outstanding breakthrough and has, at least in the short run, cured a number of patients," said Dr. Richard S. Fisher, director of the corneal disease program at the National Eye Institute in Bethesda, Md.

    The stem cells are adult, not fetal tissue, and join bone marrow and skin as the third adult stem cell in wide use to repair organs.

    In the United States, officials estimate that 300 a year are performed and that the transplants are increasing because they are the sole alternative to plastic corneas for desperate burn cases, industrial accidents, damage from contact lenses and a few rare diseases that cause blindness. In operations on one eye, 90 percent to 100 percent restore vision, because the patients' own stem cells from the good eye can be transplanted without rejection.

    In one eye, the surgery is "basically a slam dunk," said its originator, Dr. Kenneth R. Kenyon of Boston.

    "When we first saw a number of challenging cases of mostly chemical burns," he said, "the eyes were chronically inflamed, with ulcers and blood vessels growing into the cornea, hallmarks, we now know, of limbal stem cell deficiency."

    In a paper in 1989, Dr. Kenyon and Dr. Scheffer C. G. Tseng reported that ulcers and inflammation healed and invading blood vessels withdrew after the surgery. Vision improved immediately for many patients. Patients who later needed the entire cornea transplanted because other layers were scarred also had better prognoses. Those transplants were more accepted because the new stem cells resurfaced the new corneas, keeping them transparent.

    "I have some patients 20 years out with good vision," Dr. Kenyon said. "I believe these last a lifetime."

    Stem cell transplants on one eye are now standard, said Dr. R. Doyle Stulting, editor of the journal Cornea. "They are clearly successful and they are permanent," Dr. Stulting said.

    For patients blind in both eyes, stem cell transplants remain effective in half the cases after five years, principally because of rejection. Donor cells from eye banks or relatives are used, and patients require extensive antirejection drugs. In addition, injuries to both eyes from diseases like aniridia, an iris condition; Stevens Johnson syndrome, an allergic reaction to medication; and ocular cicatricial pemphigoid, an inflammatory disease, often damage lower corneal layers and require multiple operations before sight is restored.

    Surgeons report progress in those cases. Dr. Edward J. Holland, director of corneal services at the Cincinnati Eye Institute, has written the lone textbook on reconstructing the ocular surface. Last year, he announced results from 74 blind patients who received donor stem cells in both eyes.

    Seventy-three percent developed clear new corneal surfaces. In patients with no other problems, that would have meant great vision. But for those complicated cases, half of whom had aniridia, the mean vision improved, from 20/1700 before surgery to 20/200 after surgery.

  10. #10
    Junior Member
    Join Date
    Nov 2001
    Doc ,Hansen rolled around the world , Reeve lobbys everywere and for years we have had entire research centers devoted to sci and many more organizations all over the planet working hard, are we really that far behind and unorganized what the heck do we have to do

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts